Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that Sanofi-Synthelabo's Eloxatin (oxaliplatin) and Pharmacia/Aventis's Campto/Camptosar (irinotecan) will be significant contributors to the short-term growth of the colorectal cancer drug market. Eloxatin was approved as a second-line treatment for metastatic patients in the United States in August 2002 while Campto will be approved for adjuvant use sometime within the 2001 to 2006 study period of a new Pharmacor study from Decision Resources entitled Colorectal Cancer. Both these drugs will allow the market to grow at a rate of 15.8% between 2001 and 2006.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

"Eloxatin and Campto will be major factors in the growth of the colorectal cancer drug market from 2001 through 2006," said Mohamed Muhsin, analyst at Decision Resources. "However, from 2007 through 2011, the market's growth will significantly drop to 4.4% growth because irinotecan goes off-patent in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan)."

Disease Background-Colorectal Cancer

Colorectal cancer is one of the most common forms of cancer. It is the second-leading cause of malignancy-related death in the United States; in 2001, nearly 60,000 people in the United States died from the disease. The incidence of colorectal cancer is increasing -- the number of people diagnosed with the cancer in the seven major markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will grow from almost 450,000 to more than 526,000 between 2001 and 2011.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Colorectal Cancer is an Onkos report.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X17248147

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.,

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Growing Pressure to Show Results From Investments in Genomics Technologies Creates Opportunities in Drug Target Validation

View Now